Vicarious Surgical (RBOT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $13.00 price target.
Josh Jennings has given his Buy rating due to a combination of factors that highlight the promising progress of Vicarious Surgical. The company has successfully completed the integration of its Version 1.0 robotic system, marking a significant milestone in its development journey. This achievement sets the stage for the submission of a comprehensive technical dossier, which is a crucial step towards treating the first clinical patient by the end of 2025.
Despite facing supply delays, Vicarious Surgical remains on track to meet its clinical goals. The management has been proactive in identifying potential international clinical sites and is in the process of securing necessary approvals from Institutional Ethics Committees. Once these approvals are in place, the company plans to submit the dossier to the Ministry of Health, which will include detailed safety and performance data. This strategic approach positions Vicarious Surgical well for future growth and potential opportunities to strengthen its financial standing.
Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBOT in relation to earlier this year.